Galapagos NV (GLPG, Financial) experienced a significant stock price increase of 5.17%, reaching $28.29 per share with a trading volume of 302,700 shares and a turnover rate of 0.46%. The stock's price fluctuation was recorded at 3.72%.
Recent financial reports reveal that Galapagos NV generated $65.75 million in revenue, with a net loss of $53.36 million and an earnings per share (EPS) of -$0.84. The company reported a gross profit of $65.73 million and a price-to-earnings (P/E) ratio of 8.06. Among 14 rating agencies, 21% recommended buying, 71% advised holding, and 8% suggested selling the stock.
Within the biotechnology sector, which overall saw a 0.78% increase, several stocks showed notable performance. Neurosense Therapeutics Ltd, Protagenic Therapeutics Inc, and Rocket Pharmaceuticals Inc experienced significant gains. Meanwhile, Cyclerion Therapeutics, Inc., Outlook Therapeutics, Inc., and Tc Biopharm (Holdings) Plc were notably active, with high turnover rates of 991.75%, 237.45%, and 49.53%, respectively. Stocks with substantial price fluctuations included Neurosense Therapeutics Ltd, Silexion Therapeutics Corp, and Protagenic Therapeutics Inc, with amplitudes of 86.60%, 79.26%, and 78.75%.
Galapagos NV is a fully integrated biotechnology company focusing on the discovery, development, and commercialization of medicines. It aims to improve the lives of patients globally by addressing unmet medical needs, with expertise in various drug modalities, including small molecules and cell therapies. Their pipeline includes projects from discovery to commercialization in immunology, oncology, and other indications. The company’s first treatments for rheumatoid arthritis and ulcerative colitis are available in Europe and Japan, with the largest revenue coming from the United States.
